First leishmaniasis vaccine advances to human trials as disease spreads northward

Leishmaniasis affects 6 million people currently with up to 1 billion at risk; the disease causes disfigurement, disability, social stigma, and poverty, with visceral forms being fatal if untreated.

For over two decades, a single researcher's pursuit of a neglected parasite has arrived at a rare threshold: the first vaccine ever designed against leishmaniasis — a disease that disfigures, disables, and quietly spreads — has received FDA clearance to enter human trials. Engineered through CRISPR gene-editing, the vaccine revives an ancient immunization practice with modern precision, offering a potential path to protection for the billion people living in its shadow. What begins as a safety trial in Kenya, Brazil, and possibly Cincinnati carries within it the weight of a disease long dismis

First leishmaniasis vaccine advances to human trials as disease spreads northward

Cobertura Relacionada

Recibe The Register en tu bandeja